YiChang HEC ChangJiang Pharmaceutical Co., Ltd. More Details
Undervalued with moderate growth potential.
Share Price & News
How has YiChang HEC ChangJiang Pharmaceutical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 1558 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: 1558's weekly volatility (6%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: 1558 underperformed the Hong Kong Pharmaceuticals industry which returned 8.4% over the past year.
Return vs Market: 1558 underperformed the Hong Kong Market which returned 21.7% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is YiChang HEC ChangJiang Pharmaceutical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StCould The Market Be Wrong About YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Given Its Attractive Financial Prospects?
1 month ago | Simply Wall StWhat Type Of Shareholders Own The Most Number of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Shares?
2 months ago | Simply Wall StHere's Why YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Has A Meaningful Debt Burden
Is YiChang HEC ChangJiang Pharmaceutical undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 1558 (HK$7.12) is trading below our estimate of fair value (HK$30.03)
Significantly Below Fair Value: 1558 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 1558 is good value based on its PE Ratio (6.2x) compared to the Hong Kong Pharmaceuticals industry average (13.4x).
PE vs Market: 1558 is good value based on its PE Ratio (6.2x) compared to the Hong Kong market (11.5x).
Price to Earnings Growth Ratio
PEG Ratio: 1558 is poor value based on its PEG Ratio (1.6x)
Price to Book Ratio
PB vs Industry: 1558 is good value based on its PB Ratio (1.1x) compared to the HK Pharmaceuticals industry average (1.3x).
How is YiChang HEC ChangJiang Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1558's forecast earnings growth (4% per year) is above the savings rate (1.5%).
Earnings vs Market: 1558's earnings (4% per year) are forecast to grow slower than the Hong Kong market (19.4% per year).
High Growth Earnings: 1558's earnings are forecast to grow, but not significantly.
Revenue vs Market: 1558's revenue (26.3% per year) is forecast to grow faster than the Hong Kong market (12.8% per year).
High Growth Revenue: 1558's revenue (26.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1558's Return on Equity is forecast to be low in 3 years time (17.7%).
How has YiChang HEC ChangJiang Pharmaceutical performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1558 has a high level of non-cash earnings.
Growing Profit Margin: 1558's current net profit margins (35.8%) are higher than last year (30.8%).
Past Earnings Growth Analysis
Earnings Trend: 1558's earnings have grown significantly by 31.7% per year over the past 5 years.
Accelerating Growth: 1558's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 1558 had negative earnings growth (-56.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (9.2%).
Return on Equity
High ROE: 1558's Return on Equity (16.4%) is considered low.
How is YiChang HEC ChangJiang Pharmaceutical's financial position?
Financial Position Analysis
Short Term Liabilities: 1558's short term assets (CN¥3.3B) do not cover its short term liabilities (CN¥4.2B).
Long Term Liabilities: 1558's short term assets (CN¥3.3B) exceed its long term liabilities (CN¥296.4M).
Debt to Equity History and Analysis
Debt Level: 1558's debt to equity ratio (59%) is considered high.
Reducing Debt: 1558's debt to equity ratio has increased from 9% to 59% over the past 5 years.
Debt Coverage: 1558's debt is well covered by operating cash flow (43.2%).
Interest Coverage: 1558's interest payments on its debt are well covered by EBIT (4.8x coverage).
What is YiChang HEC ChangJiang Pharmaceutical current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 1558's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 1558's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 1558's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 1558's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: 1558 is not paying a notable dividend for the Hong Kong market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 1558's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Juncai Jiang (38 yo)
Mr. Juncai Jiang has been General Manager and Executive Director of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. since joining in May 2015. Mr. Jiang served as Deputy Head of the traditional Chinese med...
CEO Compensation Analysis
Compensation vs Market: Juncai's total compensation ($USD117.15K) is below average for companies of similar size in the Hong Kong market ($USD423.54K).
Compensation vs Earnings: Juncai's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
Experienced Management: 1558's management team is seasoned and experienced (6 years average tenure).
Experienced Board: 1558's board of directors are considered experienced (3.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s company bio, employee growth, exchange listings and data sources
- Name: YiChang HEC ChangJiang Pharmaceutical Co., Ltd.
- Ticker: 1558
- Exchange: SEHK
- Founded: 2001
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$6.265b
- Shares outstanding: 879.97m
- Website: https://cj.hec.cn
Number of Employees
- YiChang HEC ChangJiang Pharmaceutical Co., Ltd.
- No. 38, Binjiang Road
- Hubei Province
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. develops, manufactures, and sells pharmaceutical products in the therapeutic areas of anti-virus, endocrine and metabolic diseases, and cardiovascular diseas...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/20 10:23|
|End of Day Share Price||2021/06/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.